Evaluation of allogeneic transplantation in first or later minimal residual disease – negative remission following adult-inspired therapy for acute lymphoblastic leukemia. Issue 9 (1st September 2016)

• Record Type: Journal Article
• Authors: Cassaday, Ryan D.; Alan Potts, D.; Stevenson, Philip A.; Bar, Merav; Georges, George E.; Shustov, Andrei R.; Sorror, Mohamed L.; Wood, Brent L.; Delaney, Colleen; Doney, Kristine C.; Storb, Rainer F.; Sandmaier, Brenda M.
• Is Part Of: Leukemia & lymphoma. Volume 57:Issue 9(2016:Sep.)
• Page Start: 2109
• Page End: 2118
• Publication Date: 2016-09-01
• Subjects: Chemotherapeutic approaches -- clinical results -- lymphoid leukemia -- marrow and stem cell transplantation -- neoplasia -- prognostication; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2016.1160080
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Comparisons without hematopoietic cell transplantation (HCT) to myeloablative (MAC) or reduced-intensity HCT (RIC) for adults with acute lymphoblastic leukemia (ALL) in first minimal-residual-disease negative remission (MRD Neg CR1) are limited. Further, the importance of MRD Neg following salvage therapy (MRD Neg CR2+) is unknown. We evaluated 89 patients in MRD Neg CR1 after adult-inspired treatment: 33 received MAC (12 Philadelphia chromosome [Ph]+), 17 received RIC (13 Ph+), and 39 Deferred HCT (3 Ph+). Three-year overall survival (OS) estimates for MAC, RIC, and Deferred HCT were 71%, 69%, and 68%, while 3-year event-free survival (EFS) estimates were 65%, 54%, and 28%, respectively. Further, HCT in MRD Neg CR1 performed similarly to MRD Neg CR2+: 3-year OS estimates were 70% and 69%, and 3-year EFS estimates were 62% and 62%, respectively. In conclusion, adults with ALL in MRD Neg CR1 following adult-inspired therapy had similar OS with or without HCT, and HCT in MRD Neg CR2 + can yield long-term survival.